A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
A 15-Year Jump in Life Expectancy for People With HIV
Life Expectancy for Young People With HIV Is Nearly Normal
Failure to Awaken Dormant Cells Deals Blow to HIV Cure Research
Scientists Devise Method of Snipping HIV From Immune Cells
Media Cooks Up Claim That Soy Sauce Treats, Even Cures HIV
FDA Approves New Single-Tablet HIV Regimen, Triumeq
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


emailprint

March 6, 2013

Four in Five People With HIV and Hep C on Faldaprevir Achieve Early Treatment Success

CROI 2013Interim results from a trial of the hepatitis C virus (HCV) protease inhibitor faldaprevir, given to people coinfected with hep C and HIV, have shown an 80 percent early success rate. However, there have also been three deaths, composing 1 percent of the study cohort. Boehringer Ingelheim announced these findings of its Phase III clinical trail at the 20th annual Conference on Retroviruses and Opportunistic Infections (CROI) in Atlanta. Called STARTVerso 4, this trial is an open-label, sponsor-blinded study to assess the efficacy and safety of faldaprevir in combination with pegylated interferon and ribavirin.

The study included 308 coinfected participants who, at the study outset, were either treatment-naive or had experienced a relapse following previous hep C therapy with pegylated interferon and ribavirin. Some of the study volunteers were taking antiretrovirals (ARVs) for HIV, while others were treatment-naive. Seventeen percent of the cohort had cirrhosis.

The cohort was divided into two groups: One received either 12 or 24 weeks of a 240 mg daily dose of faldaprevir; the second group received 24 weeks of a 120 mg daily dose of faldaprevir. Both groups also received either 24 or 48 weeks of pegylated interferon and ribavirin.

After 12 weeks of treatment, 84 percent of the participants across both groups had achieved an undetectable hep C viral load. The study investigators qualified 80 percent of the group as achieving early treatment success, a result that was consistent regardless of prior hep C treatment status or HIV therapy. Those who achieved early success were qualified for randomization into a shortened course of treatment, cutting its duration from 48 to 24 weeks.

Among the most frequent adverse events were nausea (37 percent), fatigue (33 percent), diarrhea (27 percent), headache (23 percent) and weakness (22 percent). Thirty-two participants (10 percent) experienced serious adverse events; three of the patients died during the study. Thus far, 18 patients have left the study because of adverse events.

All the patients maintained HIV viral suppression throughout the study.

In a separate presentation at CROI, Boehringer Ingelheim also presented results from three open-label Phase I studies of drug-drug interactions of faldaprevir with the HIV medications boosted Prezista (darunavir/ritonavir), Sustiva (efavirenz) and Viread (tenofovir). The studies found faldaprevir did not significantly affect the way the body processes those ARVs.

To read the Boehringer Ingelheim release, click here.

Search: faldaprevir, coinfected, Boehringer Ingelheim, 20th annual Conference on Retroviruses and Opportunistic Infections, CROI, STARTVerso 4, pegylated interferon, ribavirin, Prezista, darunavir/ritonavir, Sustiva, efavirenz, Viread, tenofovir.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    fokisi
    Long Beach
    California


    zeze42
    Bay Area - Peninsula
    California


    OahuAJ
    Turlock
    California


    HOTROD2010
    houston
    Texas
Click here to join POZ Personals!
Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014


21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014


7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.